04 - Trastuzumab deruxtecan nel carcinoma mammario metastatico HER2+: attivo l'uso compassionevole in seconda linea

from "We're on the ball" - Nuovi farmaci e nuove indicazioni · host ACCMED

A cura di Alessia Levaggi Sulla base dei dati dello studio DESTINY-Breast03, AIFA ha attivato un programma a uso compassionevole che consente di utilizzare trastuzumab deruxtecan in pazienti con malattia avanzata HER2 positiva, pretrattate con trastuzumab e taxani e che abbiano ricevuto non più di una linea precedente per il setting metastatico.

Episode metadata supplied by the publisher feed · Published Jul 19, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

04 - Trastuzumab deruxtecan nel carcinoma mammario metastatico HER2+: attivo l'uso compassionevole in seconda linea

0:00 2:41

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of "We're on the ball" - Nuovi farmaci e nuove indicazioni?

This episode is 2 minutes long.

When was this "We're on the ball" - Nuovi farmaci e nuove indicazioni episode published?

This episode was published on July 19, 2022.

Can I download this "We're on the ball" - Nuovi farmaci e nuove indicazioni episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!